Stifel raised the firm’s price target on Kymera Therapeutics to $55 from $35 and keeps a Buy rating on the shares. Both the STAT6 and TYK2 programs will have preclinical data updates at medical meetings through 2024, and their first clinical data in 2025, notes the analyst, who is “compelled to start modeling KT-621 in AD for a small fraction of Dupixent’s sales.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KYMR:
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Kymera Therapeutics sees cash runway into 1H27
- Kymera Therapeutics reports Q4 EPS (25c), consensus (40c)
- Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
- Kymera Therapeutics initiated with a Peer Perform at Wolfe Research
